fadrozole has been researched along with tamoxifen in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 11 (47.83) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bogart, MH; Lance, VA | 1 |
| Hayashi, K; Kosaki, G; Shimozuma, K; Tominaga, T; Yoshida, Y | 1 |
| Bhatnagar, AS; Matter, A; Schieweck, K | 1 |
| Brodie, A; Savinov, A; Wang, J; Yue, W | 1 |
| Chinchilli, VM; Demers, L; Grossberg, H; Harvey, H; Konrad, K; Leitzel, K; Lipton, A; Teramoto, Y; Volas, G | 1 |
| Bonnefoi, HR; Coombes, RC; da Luz, RJ; Dowsett, M; Houston, SJ; Powles, TJ; Rubens, RD; Smith, IE; Trunet, PF | 1 |
| Buzdar, AU; Hortobagyi, GN; Plourde, PV | 1 |
| Falkson, CI; Falkson, HC | 1 |
| Bacchi, M; Beretta, K; Castiglione-Gertsch, M; Cavalli, F; Fey, M; Goldhirsch, A; Jungi, WF; Löhnert, T; Senn, HJ; Thürlimann, B | 1 |
| Deguchi, J; Higuchi, K; Karasawa, M; Matsuda, A; Miyamoto, M; Yoneyama, S | 1 |
| Tominaga, T | 1 |
| Dowsett, M | 1 |
| Kimura, M; Nomura, Y; Ohashi, Y; Takashima, S; Toge, T; Tominaga, T | 1 |
| Chang, CF; Du, JL; Dufour, S; Huang, JD; Lee, CY; Lee, YH; Sun, LT; Yen, FP | 1 |
| Kurebayashi, J; Sonoo, H | 1 |
| Hirayama, K; Nakajima, Y; Nishiyama, S; Saitoh, K; Shimada, T; Shimizu, T; Terashima, H | 1 |
| Buzdar, AU | 1 |
| Babiak, I; Bopopi, JM; Kestemont, P; Leprieur, F; Mandiki, SN | 1 |
| Krishnamurthy, HN; Moudgal, NR; Ramachandra, SG; Ramesh, V; Rao, AJ; Ravindranath, N | 1 |
| Cheng, CH; Hu, C; Huang, B; Huang, X; Jiao, B; Liu, Z; Nagahama, Y; Wang, D; Wang, Z; Wu, F; Zhang, X; Zhang, Y; Zhou, L | 1 |
| Blázquez, M; Navarro-Martín, L; Piferrer, F | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N | 1 |
5 review(s) available for fadrozole and tamoxifen
| Article | Year |
|---|---|
[Recent development of oral anti-cancer drugs for breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Fadrozole; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Survival Rate; Tamoxifen; Toremifene | 1999 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Estrogens; Fadrozole; Female; Humans; Letrozole; Male; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Sensitivity and Specificity; Tamoxifen; Triazoles | 1999 |
[Endocrine therapy for advanced or recurrent breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Fadrozole; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Neoplasm Recurrence, Local; Tamoxifen; Toremifene | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Estrogen receptor-positive (ER
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen | 2020 |
5 trial(s) available for fadrozole and tamoxifen
| Article | Year |
|---|---|
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens; Breast Neoplasms; Chi-Square Distribution; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Gene Amplification; Humans; Megestrol; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Regression Analysis; Survival Analysis; Tamoxifen; Treatment Outcome | 1995 |
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Confidence Intervals; Double-Blind Method; Fadrozole; Female; Flushing; Humans; Middle Aged; Nausea; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome | 1996 |
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Enzyme Inhibitors; Fadrozole; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Prospective Studies; Survival Rate; Tamoxifen | 1996 |
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Fadrozole; Female; Humans; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Tamoxifen | 1996 |
[A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen].
Topics: Aged; Aldosterone; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fadrozole; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Tamoxifen | 2000 |
13 other study(ies) available for fadrozole and tamoxifen
| Article | Year |
|---|---|
Disruption of ovarian development in alligator embryos treated with an aromatase inhibitor.
Topics: Alligators and Crocodiles; Aminoglutethimide; Androstenedione; Animals; Aromatase Inhibitors; Cyproterone; Cyproterone Acetate; Estradiol; Fadrozole; Female; Imidazoles; Male; Nitriles; Ovary; Tamoxifen; Testis | 1992 |
Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrone; Fadrozole; Female; Follicle Stimulating Hormone; Imidazoles; Luteinizing Hormone; Mammary Neoplasms, Experimental; Nitriles; Prolactin; Rats; Rats, Inbred Strains; Tamoxifen | 1990 |
CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Animals; Aromatase Inhibitors; Body Weight; Cell Line; Drug Screening Assays, Antitumor; Fadrozole; Female; Imidazoles; Mammary Neoplasms, Experimental; Nitriles; Rats; Tamoxifen | 1988 |
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Fadrozole; Female; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Organ Size; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Uterus | 1995 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 1996 |
Fourteen-day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5-fluorouracil or tamoxifen in rats.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Blood Cell Count; Blood Chemical Analysis; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fadrozole; Female; Fluorouracil; Organ Size; Ovary; Pituitary Gland; Rats; Rats, Inbred Strains; Tamoxifen; Urinalysis; Uterus; Vagina | 1997 |
Regulation of plasma gonadotropin II secretion by sex steroids, aromatase inhibitors, and antiestrogens in the protandrous black porgy, Acanthopagrus schlegeli Bleeker.
Topics: Animals; Aromatase; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fadrozole; Feedback; Female; Gonadotropins, Pituitary; Gonads; Male; Perciformes; Steroids; Tamoxifen; Testosterone | 2001 |
[An elderly woman with breast cancer and multiple liver metastasis that responded well to combination therapy of fadrozole and tamoxifen].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fadrozole; Female; Humans; Liver Neoplasms; Tamoxifen | 2001 |
Effects of sex steroids and their inhibitors on endocrine parameters and gender growth differences in Eurasian perch (Perca fluviatilis) juveniles.
Topics: Animals; Dose-Response Relationship, Drug; Endocrine Glands; Estradiol; Fadrozole; Female; Flutamide; Gonadal Steroid Hormones; Growth Hormone; Hormone Antagonists; Male; Perches; Sex Characteristics; Structure-Activity Relationship; Tamoxifen; Testosterone | 2005 |
Establishment of the need for oestrogen during implantation in non-human primates.
Topics: Animals; Antibodies; Aromatase Inhibitors; Embryo Implantation; Estradiol; Estrogen Antagonists; Estrogens; Fadrozole; Female; Macaca radiata; Menstrual Cycle; Pregnancy; Pregnancy, Animal; Progesterone; Tamoxifen | 2007 |
Molecular cloning of doublesex and mab-3-related transcription factor 1, forkhead transcription factor gene 2, and two types of cytochrome P450 aromatase in Southern catfish and their possible roles in sex differentiation.
Topics: Animals; Aromatase; Aromatase Inhibitors; Base Sequence; Catfishes; Cloning, Molecular; Estradiol; Estrogen Antagonists; Fadrozole; Female; Forkhead Transcription Factors; Gene Expression; Isoenzymes; Male; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; Sequence Alignment; Sex Differentiation; Tamoxifen; Transcription Factors | 2007 |
Masculinization of the European sea bass (Dicentrarchus labrax) by treatment with an androgen or aromatase inhibitor involves different gene expression and has distinct lasting effects on maturation.
Topics: Androgens; Animals; Aromatase Inhibitors; Bass; Cyproterone Acetate; Estradiol; Fadrozole; Female; Gonads; Male; Polymerase Chain Reaction; Receptors, Androgen; Sex Differentiation; Sexual Maturation; Tamoxifen | 2009 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |